Today’s an encouraging day for patients 12 and up with moderate to severe atopic dermatitis. The FDA has accepted Pfizer’s regulatory submission and granted Priority Review for abrocitinib, an oral once-daily jak1 inhibitor, for these patients. https://t.co/Aqbhu5EFgT
Today @Pfizer will present a full analysis of our investigational 20vPnC candidate at #IDWeek2020. With 7 additional pneumococcal serotypes, 20vPnC, if approved, will expand coverage to represent the majority of global pneumococcal disease cases. https://t.co/awvQYkpN9U